Continuing our cytokine series, we now switch horses from a creative new therapeutic utilising red blood cells that Rubius Therapeutics are pioneering to a very different technology involving synthetic amino acids, in what is known as a ‘Not Alpha’ IL–2 approach from Synthorx.
We have covered new developments in IL–2 based cytokines from Roche and Nektar previously, so what’s cool about the alternative early development that is THOR–707?
To find out, we conducted an expert interview with Synthorx’s Dr Laura Shawver and learned some fascinating details about their novel platform that is sending new molecules into the clinic in the very near future.
To learn more and get a heads up on our latest oncology insights and thought leader interviews, subscribers can log-in or you can click to gain access to BSB Premium Content.
Contemplation in Chicago ahead of #ASCO17
As part of our ongoing American Society of Clinical Research (#ASCO17) Preview series (we’re on number 5 already), we turn our attention to an upcoming area of cancer research that is expected to play an important role in future clinical trials and combination regimens because of the mechanism of action involved.
It may also turn out to be a very handy and important approach for turning cold into hot tumours.
To learn more, subscribers can login to read our latest insights and analysis
After last week’s post on therapeutic tumor infiltrating lymphocytes (TILs), we received a bunch of questions from readers.
I don’t have time to answer them all in detail individually (sorry!), but it does provide an opportunity to review the evolving landscape and address some of them within the latest article.
It seems to be a good time to take a broader look at T cell manipulation, especially as it pertains to the application of TILs, chimeric antigen receptors (CAR), and T cell receptors (TCR).
We’ve certainly come along way since the historic lecture in 1991 pictured right (photo: National Institutes of Health), but there’s still some way to go before the full potential of cancer immunotherapy is reached.
To learn more about these sentiments and insights, subscribers can log-in or you can purchase access to BSB Premium Content below…